MabPlex International, a Fremont, California-based contract research and manufacturing organization, has broken ground on the expansion of its biomanufacturing facilities in China. The current 275,000-square-foot facility will soon be running at full capacity, according to the company. The expansion, which is expected to be completed by August 2017, will include a 428,000-square-foot facility.

The current 275,000-square-foot facility will be converted entirely to antibody-drug-candidate (ADC) manufacturing and development space while the new 428,000-square-foot facility will be for monoclonal antibody (mAb) production and other biologic manufacturing.

The expansion will allow for six complete 2,000-liter bioreactor suites or six independent manufacturing lines of single-use bioreactors. Six purification suites, a 37,000-square-foot cGMP warehouse, and fill-finish lines with capabilities up to 10,000 vials per hour for mAb production and 12,000 vials per hour for ADC production will be housed in the new buildings.

Source: MabPlex International